Penumbra's STORM-PE Trial Results
Penumbra Inc.'s STORM-PE trial has yielded "resoundingly positive" results, potentially leading to a shift in guidelines for anticoagulant use in pulmonary embolism towards mechanical thrombectomy.
Experts and analysts have responded with overwhelmingly favorable comments following the presentation at the Transcatheter Cardiovascular Therapeutics symposium.
- More than 50% improvement in treatment effect with Penumbra's computer-assisted vacuum thrombectomy system plus anticoagulation compared to anticoagulation alone within two days.
- No increase in major adverse events.
Additionally, separate research has shown that genome-wide methylation analysis can provide insights into tumor behavior, and Grail LLC has presented data on the effectiveness of its Galleri circulating tumor DNA test in detecting breast, cervical, colorectal, and lung cancers.
Results from the STORM-PE trial could lead to a change in current guidelines for anticoagulant use in pulmonary embolism.
Author's summary: Penumbra's STORM-PE trial results show promise for mechanical thrombectomy in pulmonary embolism treatment.